TrialAssure, a global software company focused on developing clinical trial transparency tools-announced the full release of ANONYMIZE DS, the new software-as-a-service (SaaS) application that utilizes automation to anonymize sponsor’s clinical trial data, during the DIA Global Clinical Trial Disclosure and Data Transparency Conference. Gathering user feedback since its limited release February 2019, TrialAssure ANONYMIZE DS is now fully available to the public.
“As one of the first groups to automate the anonymization of datasets, our developers heard first-hand feedback from industry users during the limited release of the product and fine-tuned ANONYMIZE DS to best meet their needs,” says Zach Weingarden, Product Solutions Manager, TrialAssure. “As with all software we develop, our development team is open to engaging end users, actively encouraging feedback and listening carefully to their suggestions.”
Key features of TrialAssure ANONYMIZE DS, include:
“All pharmaceutical sponsors will need to rely on anonymization methods, and therefore tools, to stay ahead of transparency regulations, as redaction of data limits data utility,” says Mohamad Zahreddine, CIO, TrialAssure, and member of the Forbes Technology Council. “Transparency experts and thoughtful developers have banded together, utilizing the latest technology to build a software application that is of great importance to the future of the pharmaceutical industry, and more broadly, all those in clinical research. We want global teams to #BeTransparent, and it’s in everyone’s best interest that while we must first protect privacy, the data shared should be usable.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.